Analgesia in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation (TF-TAVI)

NCT ID: NCT03863899

Last Updated: 2020-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-02

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ilioinguinal and iliohypogastric (ILIH) nerve blocks are frequently performed for analgesia in inguinal surgery.

The investigators hypothesized that preoperative ultrasound-guided ilioinguinal and iliohypogastric (ILIH) nerve blocks will produce better intraoperative analgesia and less analgesic requirement postoperatively in comparison to commonly used preoperative local infiltration anaesthesia for patients undergoing transfemoral transcatheter aortic valve implantation (TF-TAVI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is a prospective, randomized trial.

The patients will be randomized to one of the 2 groups:

Group 1 - NERVE BLOCK. Ultrasound-guided ILIH nerve block will be performed by attending anaesthesiologist.

Group 2 - LOCAL INFILTRATION. Local anaesthetic infiltration of the operative area will be performed by operator.

During surgery patients will receive low-dose propofol infusion in order to achieve conscious sedation level, when indicated.

An extra dose of local anaesthetic drug for infiltration of the surgical field or intravenous fentanyl or/and intravenous paracetamol will be given as rescue analgesics in patients reporting pain sensation.

The patients will be observed for 24 hours. The pain at rest will be assessed using numeric rating scale (NRS 0 -10; 0 = no pain: 10 = max pain imaginable).

On the first postoperative day intravenous analgesics will be given on demand (paracetamol 1 g iv (if NRS \<5) and oxycodone 2,5 mg iv (if NRS \> or = 5)).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nerve block

ultrasound-guided ilioinguinal iliohypogastric nerve block performed by the anaesthesiologist for Transaortic valve implantation (TAVI) insertion with eventual additional intraoperative analgesia (AIA) and/or additional postoperative analgesia (APA)

Group Type EXPERIMENTAL

Nerve block

Intervention Type PROCEDURE

drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline

TAVI

Intervention Type PROCEDURE

Insertion of an aortic valve prothesis through the aorta accessed through femoral artery

Additional intraoperative analgesia

Intervention Type DRUG

Administration of any analgesics during the operation

Additional postoperative analgesia

Intervention Type DRUG

Administration of any analgesics within first 24 hours after the operation

Local infiltration

local anaesthesia infiltration performed by the operator for TAVI insertion with eventual intraoperative additional analgesia (AIA) and/or postoperative analgesia (APA)

Group Type ACTIVE_COMPARATOR

Local infiltration

Intervention Type PROCEDURE

15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)

TAVI

Intervention Type PROCEDURE

Insertion of an aortic valve prothesis through the aorta accessed through femoral artery

Additional intraoperative analgesia

Intervention Type DRUG

Administration of any analgesics during the operation

Additional postoperative analgesia

Intervention Type DRUG

Administration of any analgesics within first 24 hours after the operation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nerve block

drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline

Intervention Type PROCEDURE

Local infiltration

15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)

Intervention Type PROCEDURE

TAVI

Insertion of an aortic valve prothesis through the aorta accessed through femoral artery

Intervention Type PROCEDURE

Additional intraoperative analgesia

Administration of any analgesics during the operation

Intervention Type DRUG

Additional postoperative analgesia

Administration of any analgesics within first 24 hours after the operation

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ultrasound-guided ilioinguinal iliohypogastric nerve block Local anesthesia infiltration Transaortic valve implantation AIA APA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with aortic valve stenosis referred for TF-TAVI
* using a minimalist approach of local anesthesia or nerve block with conscious sedation

Exclusion Criteria

* patient's refusal to participate
* allergy to local anaesthetic
* TF-TAVI requiring general anesthesia or surgical cut-down
* patients with major cognitive impairment and inability to assess their pain level in Numerical Rating Scale (NRS).
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Gdansk

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Liudmila Hasak, MD, PhD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Romuald Lango, MD, PhD

Role: STUDY_CHAIR

Department of Cardiac Anaesthesiolgy UCC of Gdansk

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Clinical Centre

Gdansk, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

305/2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RESTORE-TAVI Pilot
NCT06121921 COMPLETED NA